PDGFRA is altered in 3.06% of malignant solid tumor patients with PDGFRA Amplification present in 0.75% of all malignant solid tumor patients [4].

PDGFRA Amplification is an inclusion criterion in 16 clinical trials for malignant solid tumor, of which 13 are open and 3 are closed. Of the trials that contain PDGFRA Amplification and malignant solid tumor as inclusion criteria, 6 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), and 7 are phase 2 (6 open) [5].

PDGFRA is altered in 3.59% of non-small cell lung carcinoma patients with PDGFRA Amplification present in 0.32% of all non-small cell lung carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 12 clinical trials for non-small cell lung carcinoma, of which 9 are open and 3 are closed. Of the trials that contain PDGFRA Amplification and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 8 are phase 2 (5 open) [5].

PDGFRA is altered in 1.6% of breast carcinoma patients with PDGFRA Amplification present in 0.26% of all breast carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 7 clinical trials for breast carcinoma, of which 7 are open and 0 are closed. Of the trials that contain PDGFRA Amplification and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [5].

PDGFRA is altered in 6.71% of melanoma patients with PDGFRA Amplification present in 1.7% of all melanoma patients [4].

PDGFRA Amplification is an inclusion criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain PDGFRA Amplification and melanoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

PDGFRA is altered in 2.87% of cancer patients with PDGFRA Amplification present in 0.7% of all cancer patients [4].

PDGFRA Amplification is an inclusion criterion in 4 clinical trials for cancer, of which 2 are open and 2 are closed. Of the trials that contain PDGFRA Amplification and cancer as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (1 open), and 2 are phase 2 (1 open) [5].

PDGFRA is altered in 2.72% of colorectal carcinoma patients with PDGFRA Amplification present in 0.05% of all colorectal carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 4 clinical trials for colorectal carcinoma, of which 4 are open and 0 are closed. Of the trials that contain PDGFRA Amplification and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

PDGFRA is altered in 5.52% of small cell lung carcinoma patients with PDGFRA Amplification present in 2.06% of all small cell lung carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 3 clinical trials for small cell lung carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PDGFRA Amplification and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (1 open) [5].

PDGFRA is altered in 2.26% of head and neck squamous cell carcinoma patients with PDGFRA Amplification present in 0.41% of all head and neck squamous cell carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PDGFRA Amplification and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].

PDGFRA is altered in 1.36% of non-hodgkin lymphoma patients [4].

PDGFRA Amplification is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain PDGFRA Amplification and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

PDGFRA is altered in 0.59% of pancreatic carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 3 clinical trials for pancreatic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PDGFRA Amplification and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

PDGFRA is altered in 9.64% of malignant glioma patients with PDGFRA Amplification present in 8.39% of all malignant glioma patients [4].

PDGFRA Amplification is an inclusion criterion in 2 clinical trials for malignant glioma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA Amplification and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

PDGFRA is altered in 11.11% of gastrointestinal stromal tumor patients with PDGFRA Amplification present in 1.77% of all gastrointestinal stromal tumor patients [4].

PDGFRA Amplification is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA Amplification and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

PDGFRA is altered in 5.86% of soft tissue sarcoma patients with PDGFRA Amplification present in 1.72% of all soft tissue sarcoma patients [4].

PDGFRA Amplification is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA Amplification and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

PDGFRA is altered in 5.71% of squamous cell lung carcinoma patients with PDGFRA Amplification present in 1.22% of all squamous cell lung carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA Amplification and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

PDGFRA is altered in 0.94% of hepatocellular carcinoma patients with PDGFRA Amplification present in 0.3% of all hepatocellular carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA Amplification and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

PDGFRA is altered in 1.05% of renal cell carcinoma patients with PDGFRA Amplification present in 0.23% of all renal cell carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA Amplification and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

PDGFRA is altered in 1.51% of ovarian carcinoma patients with PDGFRA Amplification present in 0.05% of all ovarian carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA Amplification and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

PDGFRA is altered in 1.68% of adenocarcinoma of the gastroesophageal junction patients [4].

PDGFRA Amplification is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA Amplification and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (2 open) [5].

PDGFRA Amplification is an inclusion criterion in 2 clinical trials for aggressive systemic mastocytosis, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA Amplification and aggressive systemic mastocytosis as inclusion criteria, 2 are phase 1 (2 open) [5].

PDGFRA is altered in 1.33% of gastric adenocarcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 2 clinical trials for gastric adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain PDGFRA Amplification and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [5].

PDGFRA Amplification is an inclusion criterion in 2 clinical trials for mast cell leukemia, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA Amplification and mast cell leukemia as inclusion criteria, 2 are phase 1 (2 open) [5].

PDGFRA Amplification is an inclusion criterion in 2 clinical trials for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 2 are open and 0 are closed. Of the trials that contain PDGFRA Amplification and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 2 are phase 1 (2 open) [5].

PDGFRA is altered in 2.63% of urothelial carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA Amplification and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

PDGFRA is altered in 10.04% of glioblastoma patients with PDGFRA Amplification present in 9.37% of all glioblastoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains PDGFRA Amplification and glioblastoma as inclusion criteria, 1 is phase 2 (0 open) [5].

PDGFRA is altered in 6.29% of osteosarcoma patients with PDGFRA Amplification present in 7.42% of all osteosarcoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PDGFRA is altered in 7.66% of glioma patients with PDGFRA Amplification present in 6.4% of all glioma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for glioma, of which 0 are open and 1 is closed. Of the trial that contains PDGFRA Amplification and glioma as inclusion criteria, 1 is phase 2 (0 open) [5].

PDGFRA is altered in 7.35% of WHO grade III glioma patients with PDGFRA Amplification present in 4.6% of all WHO grade III glioma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for WHO grade III glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 2.33% of pecoma patients with PDGFRA Amplification present in 2.53% of all pecoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PDGFRA is altered in 2.78% of nasopharyngeal carcinoma patients with PDGFRA Amplification present in 2.33% of all nasopharyngeal carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 3.42% of undifferentiated pleomorphic sarcoma patients with PDGFRA Amplification present in 2.31% of all undifferentiated pleomorphic sarcoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for undifferentiated pleomorphic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PDGFRA is altered in 2.17% of malignant salivary gland neoplasm patients with PDGFRA Amplification present in 2.06% of all malignant salivary gland neoplasm patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 2.14% of head and neck carcinoma patients with PDGFRA Amplification present in 0.96% of all head and neck carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 1.34% of chondrosarcoma patients with PDGFRA Amplification present in 0.91% of all chondrosarcoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PDGFRA is altered in 1.37% of malignant germ cell tumor patients with PDGFRA Amplification present in 0.84% of all malignant germ cell tumor patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for malignant germ cell tumor, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and malignant germ cell tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

PDGFRA is altered in 2.0% of liposarcoma patients with PDGFRA Amplification present in 0.46% of all liposarcoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PDGFRA is altered in 3.66% of lung carcinoma patients with PDGFRA Amplification present in 0.4% of all lung carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 1.47% of lip and oral cavity carcinoma patients with PDGFRA Amplification present in 0.3% of all lip and oral cavity carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 1.08% of hepatobiliary neoplasm patients with PDGFRA Amplification present in 0.27% of all hepatobiliary neoplasm patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 1.08% of malignant hepatobiliary neoplasm patients with PDGFRA Amplification present in 0.27% of all malignant hepatobiliary neoplasm patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 0.74% of thyroid gland carcinoma patients with PDGFRA Amplification present in 0.19% of all thyroid gland carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PDGFRA is altered in 0.75% of bile duct carcinoma patients with PDGFRA Amplification present in 0.12% of all bile duct carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 0.75% of cholangiocarcinoma patients with PDGFRA Amplification present in 0.12% of all cholangiocarcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 4.53% of endometrial carcinoma patients with PDGFRA Amplification present in 0.1% of all endometrial carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PDGFRA is altered in 3.44% of malignant uterine neoplasm patients with PDGFRA Amplification present in 0.07% of all malignant uterine neoplasm patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 1.11% of prostate carcinoma patients with PDGFRA Amplification present in 0.06% of all prostate carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [5].

PDGFRA is altered in 2.73% of bladder carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 1.57% of cervical carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for desmoid-type fibromatosis, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and desmoid-type fibromatosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PDGFRA is altered in 11.76% of diffuse intrinsic pontine glioma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 1.3% of esophageal carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 2.74% of esophageal squamous cell carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PDGFRA is altered in 1.09% of gallbladder carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 1.32% of gastric carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 1.02% of hematologic and lymphocytic disorder patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [5].

PDGFRA is altered in 0.7% of hematopoietic and lymphoid malignancy patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [5].

PDGFRA is altered in 0.73% of hematopoietic and lymphoid system neoplasm patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

PDGFRA is altered in 0.37% of histiocytic and dendritic cell neoplasm patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 1.19% of malignant laryngeal neoplasm patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 0.41% of multiple myeloma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 0.65% of myelodysplastic syndromes patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [5].

PDGFRA is altered in 0.53% of myeloid neoplasm patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

PDGFRA is altered in 2.9% of nasal cavity and paranasal sinus carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 1.42% of oropharyngeal carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 7.69% of penile carcinoma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and penile carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

PDGFRA is altered in 3.45% of systemic mastocytosis patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) [5].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRA is altered in 3.18% of WHO grade II glioma patients [4].

PDGFRA Amplification is an inclusion criterion in 1 clinical trial for WHO grade II glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA Amplification and WHO grade II glioma as inclusion criteria, 1 is phase 2 (1 open) [5].